Full Coverage

Gilead Sciences' lenacapavir receives FDA approval for HIV prevention

Posts on X

Formerly Twitter
Gilead Sciences
GileadSciences
We’ve been working to advance #HIV innovation for decades, and we’re committed to creating options that help address the diverse needs and preferences of people who need or want PrEP. Hear the perspectives from three HIV advocates on the value of HIV prevention. pic.x.com/Fg4wH4a0C9
Posted on X
Gilead Sciences
GileadSciences
Since our researchers developed the first single-dose, daily HIV tablet in 2006, Gilead has been at the forefront of helping transform #HIV from a serious disease to one that can be effectively treated and prevented. Read more about our work: gilead.inc/4k2R60G. pic.x.com/Q5oeFkEtsB
Posted on X
Unitaid
UNITAID
We’ve seen what’s possible when access is prioritized. Let’s ensure lenacapavir delivers impact, not just headlines. Thanks to @NPR's @evolambert for reporting on both the scientific breakthrough and the equity challenge. Learn more: www.npr.org/sections/goats-and-soda/2025/06/18/g-s1-73130/hiv-prevention-drug-lenacapavir-fda-breakthrough
Posted on X
Atul Gawande
Atul_Gawande
Lenacapavir, a twice-yearly shot that almost completely prevents HIV, is now approved. It could shut down the HIV pandemic. It needs to roll out in at risk groups. But Trump has gutted HIV prevention at home and abroad. www.nytimes.com/2025/06/18/health/hiv-fda-lenacapavir.html?unlocked_article_code=1.QE8.8WDW.QCXqyEc9P1XE&smid=url-share
Posted on X

All coverage

HomeFollowing
Search
Clear search
Close search
Google apps
Main menu